Christoph A. Thaiss

TL;DR: Altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.

TL;DR: It is shown that deficiency of NLRP6 in mouse colonic epithelial cells results in reduced IL-18 levels and altered fecal microbiota characterized by expanded representation of the bacterial phyla Bacteroidetes (Prevotellaceae) and TM7.

TL;DR: It is demonstrated that consumption of commonly used NAS formulations drives the development of glucose intolerance through induction of compositional and functional alterations to the intestinal microbiota, thereby calling for a reassessment of massive NAS usage.

TL;DR: It is proposed that understanding this microbial influence will be crucial for targeted therapy in modern cancer treatment and the recently suggested role of commensal microorganisms in inflammation-induced cancer is discussed.

TL;DR: The intestinal microbiome is a signalling hub that integrates environmental inputs, such as diet, with genetic and immune signals to affect the host's metabolism, immunity and response to infection.